Cancer Treatment–Induced Bone Loss (CTIBL): State of the Art and Proper Management in Breast Cancer Patients on Endocrine Therapy

About 70–80% of early breast cancer (BC) patients receive adjuvant endocrine therapy (ET) for at least 5 years. ET includes in the majority of cases the use of aromatase inhibitors, as upfront or switch strategy, that lead to impaired bone health. Given the high incidence and also the high prevalenc...

Descripción completa

Detalles Bibliográficos
Autores principales: Diana, Anna, Carlino, Francesca, Giunta, Emilio Francesco, Franzese, Elisena, Guerrera, Luigi Pio, Di Lauro, Vincenzo, Ciardiello, Fortunato, Daniele, Bruno, Orditura, Michele
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2021
Materias:
Breast Cancer (WJ Gradishar, Section Editor)
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8052225/
https://www.ncbi.nlm.nih.gov/pubmed/33864145
http://dx.doi.org/10.1007/s11864-021-00835-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8052225/
https://www.ncbi.nlm.nih.gov/pubmed/33864145
http://dx.doi.org/10.1007/s11864-021-00835-2

Ejemplares similares